Lilly paid an undisclosed sum upfront for Kelonia Therapeutics on Monday, placing a large bet on in vivo CAR-T as its next platform priority.
The “upfront” framing signals there’s more on the table. Lilly isn’t paying what Kelonia is worth today; it’s paying for what the platform could become.
In vivo CAR-T sits at the center of this deal. Traditional cell therapy removes a patient’s T cells, engineers them outside the body, and reinfuses them. In vivo approaches aim to deliver the reprogramming instructions directly inside the patient, potentially cutting both the manufacturing cost and the clinical complexity. That’s the bottleneck Lilly is paying to eliminate.
What does Lilly actually get? Kelonia’s in vivo delivery platform. Lilly is paying for the platform, not the proof.
The deal was announced Monday. Whether the milestone structure makes this price look disciplined or stretched is the first question Lilly’s investors will ask.
Diana Kowalski